Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
311.00    -14.00 (-4.31%)
Bid:
310.00
Ask:
312.00
Spread: 2.00 (0.645%)
Market Cap: £39.46m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Trading Update

15 Jul 2016 07:00

RNS Number : 2623E
BrainJuicer Group PLC
15 July 2016
 

 

 

 

Press Release

15 July 2016

 

 

BrainJuicer Group PLC (AIM: BJU)

("BrainJuicer", or "the Company")

 

Six month Trading Update

 

BrainJuicer, the innovative international market research agency, today releases the following six month ("H1") trading update. The Company will announce its interim results for the six months to 30 June 2016 on 16 September 2016.

 

Top line growth during H1 was generally encouraging. Revenue increased by 13%, and by 9% in constant currencies, and gross profit (our main top-line performance indicator) grew by 15%, and 11% in constant currencies. Our largest market, the US, performed strongly, with gross profit rising by some 27%; gross profit in Continental Europe and Brazil also grew well, increasing by 30% and 22% respectively. Gross profit in our second largest market, the UK, declined by 2%, and in our China and Singapore region it also declined slightly by 5%.

 

Our Ad Testing and Brand Tracking services continued to grow strongly, with gross profit up 59% year on year. Much of this business is Ongoing in nature (as opposed to Ad Hoc), and builds on the "Fame, Feeling & Fluency" approach to brand building that we introduced last year.

 

After factoring in our new creative agency, System1, which was launched during H1 and, as anticipated, incurred costs of some £0.3m, BrainJuicer's operating profit increased by some 41% to around £1.7m. After adjusting for exceptional items (share based payments and also the one-off costs in H1 2015 relating to due diligence work and our Head Office move) normalized H1 pre-tax profit will be similar to the £1.7m reported in 2015.

 

BrainJuicer's financial position remains strong. At the end of June the Company had a cash balance of £5.2m (December 2015: £6.4m), after returning £2.2m to shareholders during H1 by way of dividends and share buy-backs.

The Company generates the majority of its annual profit in the second half of the year, and whilst our revenue visibility is, as ever, limited the Board believes that the Company is in a position to meet market expectations for the full year.

 

The decline in the value of sterling versus the US Dollar, the Euro and other leading currencies following the referendum on the UK's membership of the EU benefits the Company's non-UK profits reported in sterling. The results of our overseas businesses are translated into sterling using monthly average exchange rates. Beyond this, it is too early to say what the impact of the UK's exit from the EU on the market research budgets of our clients is likely to be.

 

This announcement contains inside information. The Company can be found at www.brainjuicer.com.

 

For further information, please contact:

BrainJuicer Group PLC

Tel: +44 (0)20 7043 1000

 

John Kearon, Chief Executive Officer

 

James Geddes, Chief Financial Officer

 

Canaccord Genuity Limited

Tel: +44 (0)20 7523 8000

Simon Bridges / Henry Fitzgerald-O'Connor / Emma Gabriel

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUSABRNWABAAR
Date   Source Headline
24th Mar 20101:22 pmRNSDirector/PDMR Shareholding
10th Mar 20103:11 pmRNSBlocklisting Interim Review
10th Mar 20103:05 pmRNS2009 Final Dividend
10th Mar 20107:38 amRNS2010 Interim Dividend
9th Mar 20107:00 amRNSFinal Results
1st Feb 20107:00 amRNSAlex Batchelor Appointed COO
19th Jan 20107:00 amRNSTrading Update
4th Jan 20102:10 pmRNSShare Dealings
22nd Sep 20097:00 amRNSInterim Dividend
22nd Sep 20097:00 amRNSInterim Results
1st Sep 20097:00 amRNSNotice of Results
8th Jul 200912:46 pmRNSShare Dealings
8th Jul 20097:00 amRNSTrading Statement
13th May 200910:20 amRNSResult of AGM
17th Apr 20097:00 amRNSNotice of AGM
16th Apr 20093:15 pmRNSFinal Dividend
2nd Apr 20097:00 amRNSTrading on Sharemark
19th Mar 20097:00 amRNSPreliminary Results
5th Feb 200910:35 amRNSBlocklisting Interim Review and TVR
19th Jan 20097:00 amRNSPre-Close Trading Statement
13th Jan 200910:41 amRNSDirector's Dealings
9th Jan 20092:18 pmRNSDirector's Dealings
9th Dec 20087:00 amRNSExercise of Share Options
25th Nov 20087:00 amRNSDirector/PDMR Shareholding
13th Nov 20087:00 amRNSChange of Adviser
8th Oct 20086:02 pmRNSChange of Adviser Name
5th Sep 20087:00 amRNSInterim Results
4th Aug 20081:08 pmRNSBlocklisting Interim Review
1st Jul 20087:00 amRNSPre-Close Trading Statement
16th Jun 20087:00 amRNSGlobal Expansion
21st May 20084:40 pmRNSResult of AGM
10th Mar 20087:01 amRNSFinal Results
29th Feb 20087:00 amRNSTotal Voting Rights
25th Feb 20087:01 amRNSBlock Listing
12th Feb 20087:00 amRNSNotice of Results
11th Feb 20087:01 amRNSGlobal strategy
15th Jan 20087:00 amRNSTrading update
28th Dec 20074:51 pmRNSDirectors Dealing error
28th Dec 200711:38 amRNSDirectors Dealings
30th Nov 20077:00 amRNSIssue of Equity & TVR
31st Oct 20077:01 amRNSTotal Voting Rights
12th Oct 20077:01 amRNSIssue of Equity
20th Sep 20077:02 amRNSIndustry Award Winner
14th Sep 20071:15 pmRNSDirector/PDMR Shareholding
13th Sep 20077:01 amRNSInterim Results
5th Sep 20075:44 pmRNSNon-Exec Chairman Appointment
5th Sep 20077:01 amRNSNon-Exec Chairman Appointment
4th Sep 20077:01 amRNSNotice of Results
15th Aug 20078:10 amRNSAIM 26 and NOMAD name change
11th Jun 20077:02 amRNSCreativity Test

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.